Mallinckrodt
Specialty pharmaceutical developer, manufacturer, distributor
Associate Director Government Pricing
+ Bonus
More locations: Bridgewater, NJ, USA | Hazelwood, MO, USA
Three days on-site per week required.
About the job
- A bachelor's degree in Accounting, Finance, Business, or Economics is required.
- At least 8 years of progressive experience in pharmaceutical Government Pricing, Medicaid or Medicare reimbursement, pricing policy, or regulatory compliance is required.
- Deep technical expertise in Average Manufacturer Price, Best Price, Average Sales Price, Unit Rebate Amount, 340B, and Federal Supply Schedule or Veterans Affairs pricing is required.
- Strong analytical, quantitative, and decision-making skills, including the ability to interpret complex regulations, are required.
- The role requires excellent communication, cross-functional collaboration, and presentation skills.
- The role requires the ability to manage multiple priorities in a fast-paced, compliance-driven environment.
- The role requires high ethical standards and a strong commitment to accuracy and compliant reporting practices.
- Assist with providing oversight for the calculation, review, audit, and submission of federal pricing values, including Average Manufacturer Price, Best Price, Average Sales Price, Non-Federal Average Manufacturer Price, 340B Public Health Service Ceiling Price, Federal Ceiling Price, Unit Rebate Amount, Medicare Part B inflationary rebates, and Medicare Part D inflationary rebates.
- Assist with identifying and tracking bona fide service fees according to required Centers for Medicare & Medicaid Services qualitative and quantitative Fair Market Value assessments and obtain and submit customer bona fide service fee certifications.
- Provide review and approval for quarterly Medicaid and Medicare rebates.
- Assist with resolving complex pricing issues, data anomalies, restatement decisions, and methodology assessments.
- Provide leadership support for Federal Supply Schedule contract renewals and the annual Public Law process.
- Ensure the alignment and accuracy of government-pricing data used in Gross to Net forecasting and accruals.
- Partner with Commercial Finance to maintain a comprehensive financial forecast model incorporating current government-pricing and rebate assumptions.
- Assist with the annual review and update of Government Pricing policies, reasonable assumptions, standard operating procedures, and calculation methodologies.
- Assist with oversight of system configuration, master-data accuracy, adherence to approved methodologies, and internal controls.
- Strengthen internal controls, documentation standards, and compliance frameworks related to government-pricing processes.
- Coordinate with Information Technology and Model N support teams to address system issues, manage updates, and maintain data integrity.
- Approve and oversee testing, validation, and governance for system integrations, upgrades, enhancements, and regulatory changes affecting government-pricing calculations.
- Provide leadership oversight and subject-matter support for state drug-price-transparency submissions, including price increases, new-drug reporting, and cost or wholesale-acquisition-cost changes.
- Support interpretation of emerging state legislation and oversee operational implementation.
- Partner with Legal, Government Affairs, and Compliance to monitor regulatory changes and assess their operational impact.
- Work with Market Access, the Gross to Net Payments Team, and a third-party vendor to analyze and optimize the 340B or Medicaid duplicate-discount review and recovery process.
- Lead cross-functional discussions on government-pricing implications of contract strategy, pricing actions, and commercial decision-making.
- Provide training, education, and subject-matter expertise to internal stakeholders.
- Represent the Government Pricing function in audit discussions, compliance reviews, and strategic initiatives.
- Maintain and enhance standard operating procedures, policies, process flows, and governance documentation across government price reporting.
- An advanced degree is preferred.
- A Master of Business Administration or Certified Public Accountant credential is preferred.
- Prior leadership or team-management experience is strongly preferred.
- Strong working knowledge of state drug-price-transparency requirements is preferred.
- Experience with Model N or a similar government-pricing system is strongly preferred.
About the company
Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hazelwood, Missouri
Founded
1867
Get referred to Mallinckrodt
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 Acthar Gel net sales reached $205 million, up 17%.
- August 11, 2026 guidance raised, with 2026 pro forma sales up to $2.0 billion.
- Management now plans a 2027 NYSE listing after integration progress.
What critics are saying
- Maine DEP sued Mallinckrodt US LLC on August 25, 2026 over Orrington cleanup failures.
- Keenova reported a $221 million Q2 2026 loss from continuing operations.
- A failed 2027 NYSE listing traps Keenova with debt, litigation, and reputational damage.
What makes Mallinckrodt unique
- Keenova’s Acthar Gel and XIAFLEX franchises drive branded rare-disease cash flows.
- July 31, 2025 Endo merger combined branded therapies with scale and synergies.
- November 2025 Par Health spinout left a pure-play specialty therapeutics company.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site. The Department of Environmental Protection has filed a lawsuit against Mallinckrodt US LLC, accusing the company of failing to clean up mercury contamination at its site in Orrington. The department filed the complaint in Penobscot Superior Court Tuesday, and in court records the department said the company has stopped "meaningful work" at the site despite department orders and notices of violations. Jesse Graham is the co-director of the Maine People's Alliance - which, independent from the state enforcement actions, sued Mallinckrodt over the contamination in federal court in 2000. "We have for a long time been calling for the thorough cleanup of that site, and we have definitely been disappointed that Mallinckrodt has not cleaned it up to the standards that the Maine DEP has set," Graham said. "We fully support the Maine DEP continuing to pressure them and whatever legal tactics they need to do to compel them to finish and do a thorough cleanup of all the pollution that Mallinckrodt has left on the site." Considered the most contaminated site in Maine, the property is the former HoltraChem chloralkali manufacturing facility. Located adjacent to the Penobscot River, the facility operated from 1967 through 2000, and manufactured caustic soda, chlorine bleach and pesticides. In court documents, the department said Mallinckrodt has complained about the difficulties and high costs of cleaning up the site. But, the department said, "this is no excuse for Mallinckrodt's ongoing failure to adhere to the cleanup standards and other requirements of the orders." The department is asking the court for civil penalties, and to order Mallinckrodt to comply with all department orders and submit a plan to remove all soil and solid materials from the site. Attempts to reach someone who could speak on behalf of Mallinckrodt were unsuccessful. The DEP and the U.S. Environmental Protection Agency first began pursuing clean up at the site in the mid-1980s, including negotiations with the company in 2002. But after failing to reach an agreement, in 2008 the department issued a unilateral cleanup order for the site. But Mallinckrodt appealed that order, first to the Board of Environmental Protection, and then in state courts. Ultimately, the state supreme court upheld the department's order in 2014. The department issued notices of violations to Mallinckrodt in May and October of 2025, over the ongoing issues, but said the company still failed to address the shortcomings of their proposed cleanup plans. There is also the federal court case filed by the Maine People's Alliance, which is separate from the state proceedings involving the department. In 2022, Mallinckrodt settled the federal case, and agreed to pay at least $187 million to address mercury pollution in the Penobscot River. Graham said some of that agreed-up work is underway now, as Mallinckrodt adds sand to several coves along the river with high levels of mercury, a process known as "capping."
DEP sues to compel cleanup of 'most contaminated site in Maine' BY Susan Cover Maine PUBLISHED 10:13 AM ET Aug. 27, 2026 AUGUSTA - State officials are escalating action against a company they say has failed to clean up "the most contaminated site in Maine" after more than 20 years of lawsuits. The Maine Department of Environmental Protection filed a formal complaint Tuesday in Penobscot County Superior Court against Mallinckrodt US LLC. The state alleges that the company has failed to clean up the former HoltraChem site on the Penobscot River in Orrington. The site "discharged to the environment tons of mercury and thousands of tons of mercury-contaminated brine-sludge, substances that are defined as hazardous wastes," according to the lawsuit. The facility made chemicals commonly used in the pulp and paper industry, according to DEP. It operated under various owners from 1967 to 2000. The company did not respond to a request for comment. The suit says the facility covered about 235 acres near the river, 77 of which were affected by the production. The site included five landfills, a manufacturing facility and waste piles. In the mid-1980s, the U.S. Environmental Protection Agency and the state began investigating the site and calling for remediation. According to the suit, in 2000, the Maine People's Alliance and the Natural Resources Defense Council filed a lawsuit against the company alleging that the company "discharged mercury from the site into the Penobscot River and that these discharges resulted in an imminent and substantial danger to public health and the environment." A court ordered the company to come up with a remediation plan. The latest lawsuit asks the court to remove contaminated soil and industrial sewer lines, assess civil penalties and require the company to comply with all DEP orders.
Maine DEP sues company over cleanup of contaminated Orrington site. Mallinckrodt US LLC operated a chemical manufacturing plant along the Penobscot River in Orrington that discharged up to a dozen metric tons of mercury in the late 1960s and early 1970s. Community: Posted 7:54 PM Updated at 7:54 PM The Maine Department of Environmental Protection is suing the owners of a site in Orrington, alleging they've failed to properly clean up contamination. The Maine DEP announced the legal action in Penobscot Superior Court against Mallinckrodt US LLC on Tuesday. The department is seeking injunctive relief and civil penalties. The company operated a chemical manufacturing plant along the Penobscot River in Orrington between 1967 and 1982. While under Mallinckrodt's control, the site discharged between six and 12 metric tons of mercury in the late 1960s and early 1970s, according to one court-ordered study. Please add a subscription to your account to access this story. Choose a plan to keep reading. Starter Digital $1 for 4 weeks * | 4 weeks of access for $1 * | Full access to our websites, ePapers and app * | Newsletters, archives, puzzles and games * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household Annual Digital $99 per year Billed annually - Save 56% * | One year of access for $99 * | Full access to our websites, ePapers and app * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household
Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...
Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.